Enhanced Genomics appoints Dietrich Stephan, Ph.D. as Chair of the Board to lead ambitious growth strategy

Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery Cambridge, UK, 10 June 2025: Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced the appointment of […]

Read more

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Cambridge, UK, 14 January 2025: Enhanc3D Genomics (‘Enhanced’ or ‘the Company’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery. Based on the Company’s proprietary 3D genomics platform, integrated with extensive multi-omics analysis, the new 3D Multi-omic offerings […]

Read more

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships

Read more

Enhanc3D Genomics expands leadership team with the appointment of Hazel Jones as Chief Operating Officer

Key appointment supports company growth and strategic commercial and academic partnerships Cambridge, UK, 06 November 2023: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer. Following a £10 million Series A financing in October 2022, […]

Read more

Enhanc3D Genomics honoured at the Falling Walls 2023

Falling Walls 2023 We are honoured to be selected as a winner in the Science Start-ups/ #FallingWallsVenture category of the Falling Walls Foundation #GlobalCall23! This recognition underscores our commitment to driving positive change in the life sciences. We are looking forward to connecting with fellow innovators and to discuss our exciting platform at the Falling Walls #ScienceSummit2023 in Berlin on 7–9 […]

Read more

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

GenLink3DTM provides the first high-resolution mapping of DNA interactions in 3D space, enabling the vast array of non-coding genetic variations to be deciphered into actionable disease biomarkers and treatment targets Funds will be used to rapidly generate deep datasets of novel diagnostic signatures and candidate therapeutic targets across multiple immune-related diseases for internal and external […]

Read more

OnHelix conference

We had a great day at OnHelix conference held at Babraham Institute focussed on translating research into diagnostics and therapeutics. #onhelix22 #3DGenomics

Read more

ENHANC3D was spun out of Professor Peter Fraser’s pioneering 3D genome organisation research laboratory

We are developing a technology to unlock the full potential of the 3D organisation of the #humangenome to identify #disease-associated #genetic interactions including those that are causal for disease susceptibility and progression.

Read more

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

We are proud to be awarded the Johnson & Johnson Innovation QuickFire Challenge Grant which recognises the potential of our functional genomics platform, GenLink3D™.

Read more